Tomoya Sugimoto

Tomoya Sugimoto

Auto-generated profile, based on publicly available information

Tomoya Sugimoto

Endowed Course of Advanced Medical Care Community Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Japan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2025 in Oncology
Verified
Journal Article
Closed access
TSTomoya Sugimoto
Tomoya Sugimoto
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
RMRikuto Masuda
Rikuto Masuda
THTomohiko Harada
Tomohiko Harada
YTYukio Toyama
Yukio Toyama
TYTomoaki Yoshimura
Tomoaki Yoshimura
Introduction: This study aimed to evaluate the trends in safety signal detection of osimertinib compared with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) through volcano plot analysis, using data from the Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS). The overall objective of this study was to identify the potential risks associated with osimertinib-induced adverse events. Methods: Data were retrieved from the JADER (Q1 2004–Q1 2024) and FAERS (Q4 1997–Q2 2024) databases. The target drugs were osimertinib, gefitinib, erlotinib, and afatinib. Adverse event reports were standardized by converting all records in the database to the preferred terms of the International Classification of Diseases and subsequently mapping them to the high-level terms (HLTs) of the Medical Dictionary for Regulatory Activities. Volcano plots of odds ratios and z scores were generated to assess variations in detection trends between osimertinib and the abovementioned three EGFR-TKIs. The top 20 HLTs that demonstrated significant safety signals were computed and compared. Results: The numbers of safety signals detected in the JADER for osimertinib compared to the aforementioned EGFR-TKIs following volcano plot analysis were 24, 20, and 16, whereas detected safety signals were 7, 43, and 14 in FAERS. In the JADER database, the most frequently reported adverse reactions for osimertinib included “poisoning and toxicity” and “heart failure.” Conversely, in the FAERS database, the predominant adverse reactions were “death and sudden death” and “marrow depression and hypoplastic anemias.” Conclusion: This study confirmed an increased frequency of reports linking osimertinib to cardiotoxicity, bone marrow suppression, and anemia. However, interstitial pneumonia, previously considered a risk factor, was not identified. When evaluating risks influenced by racial and treatment-related factors, caution must be exercised regarding potential discrepancies between reported rates and true incidence.

17 September 2026 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
THTomohiko Harada
Tomohiko Harada
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
AOAi Ohnishi
Ai Ohnishi
RMRikuto Masuda
Rikuto Masuda
TSTomoya Sugimoto
Tomoya Sugimoto
TYTomoaki Yoshimura
Tomoaki Yoshimura
Background Nivolumab was initially approved with body weight-based dosing; however, fixed-dose regimens were later adopted based on pharmacokinetic evidence supporting comparable benefit–risk profiles. Nevertheless, the acquisition cost impact of fixed dosing relative to a body weight-based counterfactual remains unclear in Japanese real-world data. Objectives The purpose of this study was to estimate drug acquisition cost differences at the index administration by comparing observed fixed-dose quantities with a simulated body weight-based counterfactual using nationwide Japanese claims data. Methods We retrospectively analyzed nationwide Japanese claims data. Fixed-dose regimens of 80, 240, 360, and 480 mg were mapped to corresponding body weight-based regimens of 1, 3, 4.5, and 6 mg/kg, respectively, and patient-specific body weight-based doses were calculated using recorded body weight. The index administration was the first nivolumab administration observed for each patient during the database observation period. Costs were estimated at the index administration using official Japanese drug prices. Sensitivity analyses examined alternative body weight measurement windows and simulated measurement error. Bootstrap resampling was used to estimate uncertainty in the median cost difference. Results Among 3243 patients, estimated drug acquisition costs based on observed fixed-dose quantities were higher than those calculated for the simulated body weight-based counterfactual at the index administration. The median cost difference was 89,540 Japanese yen (bootstrap 95% confidence interval 86,945–92,135 Japanese yen). Median costs were 311,443 and 251,750 Japanese yen for observed fixed-dose quantities and the simulated body-weight-based counterfactual, respectively. The direction of the estimated cost difference remained consistent across sensitivity analyses, although its magnitude varied across simulated body weight measurement-error scenarios. Conclusions Using real-world Japanese claims data and official drug prices, this study estimated higher acquisition costs based on observed fixed-dose quantities than those calculated for a simulated body-weight-based counterfactual at the index administration. The body-weight-based comparator was simulated for the same patients and did not represent an observed treatment group.